Last week, the U.S. Food and Drug Administration and the Disease Control and Prevention authorized and recommended boosters of both the Moderna and Johnson & Johnson (J&J) COVID-19 vaccines. Moderna’s booster comes in just a half dose, and is recommended for people over 65, people over 50 with certain conditions, and people who work in high-exposure jobs. For J&J vaccine recipients, boosters were recommended for everyone over 18.
Though the CDC recommended that people boost with the vaccine they started with, they also endorsed a “mix n’ match” approach. This is particularly salient for Americans who received the J&J vaccine, considering its laggard performance in preventing breakthrough delta infections relative to its mRNA cousins.
Indeed, a recent National Institutes of Health study found that among people whose first vaccination was with J&J, receiving a second J&J dose led to a four-fold increase in antibody reactivity in a test tube. But boosting with Pfizer led to a 35-fold increase — and boosting with Moderna led to a 76-fold increase.
A different U.K.-based study showed that among recipients of the AstraZeneca vaccine (which, like J&J, uses an adenovirus vector rather than mRNA), boosting with the Pfizer vaccine increased in vitro antibody reactivity vastly more than a second dose of AstraZeneca.
One study looked at whether these in vitro studies translate into real protection from infection. This study, out of Umea, Sweden found that AstraZeneca recipients who crossed over to Pfizer boosters had a 67% lower infection rate while those who took Moderna boosters had a 79% lower infection rate than AstraZeneca double-vaxxers.
There’s a good biological reason why crisscrossing vaccines could be beneficial. Consider the (admittedly ableist) old proverb about blind men identifying an elephant. If each of them has only ever felt a part of the elephant, each leaves with a different sense of what the elephant is. If he was introduced to a different part, he might mistake it for something else. It’s a helpful analogy for understanding how our immune systems identify the virus. Every time we receive a vaccine, we’re showing it one part of the proverbial elephant. But if you show it different parts, it gets a better picture of what the thing is — and can fight it off faster.
That said there’s a curious thing about booster crossover. Though studies show that receiving an mRNA vaccine after an adenovirus vaccine improves antibody reactivity, the opposite isn’t true. In the U.K. study I mentioned earlier, those who received two Pfizer vaccines had a higher reactivity than those who received AstraZeneca after Pfizer. It may just be that the mRNA vaccines are simply better over the long term against delta.
But there’s a bigger issue here. In the grand scheme of the COVID-19 pandemic, which boosters people receive — let alone if they receive boosters at all — is less important than if those who have yet chosen to remain unvaccinated get vaccinated in the first place. The whole conversation about boosters highlights a broader tale of two pandemics. There’s the pandemic of the unvaccinated, among whom delta has torn, killing thousands upon thousands of unvaccinated people who by dint of political sorting have the misfortune of also living among other unvaccinated people. And there’s the pandemic among the vaccinated, among whom a relatively small number of breakthrough delta cases have mostly led to short-lived mildly symptomatic illness, but which have also driven the clamor for boosters. While boosting is probably a good choice for individuals, let’s not assume that it’s the solution to COVID-19.
So go on and get your booster if you’re eligible — but unlike your first doses, don’t assume that the booster’s going to change the course of the pandemic. To do that, you’re better off trying to convince that friend or family member who hasn’t gotten their first dose yet.Originally published Oct. 26 in The Incision. Get more incision.substack.com.
We welcome readers to submit letters regarding articles and content in Detroit Metro Times. Letters should be a minimum of 150 words, refer to content that has appeared on Detroit Metro Times, and must include the writer's full name, address, and phone number for verification purposes. No attachments will be considered. Writers of letters selected for publication will be notified via email. Letters may be edited and shortened for space.
Email us at [email protected].
Support Local Journalism.
Join the Detroit Metro Times Press Club
Local journalism is information. Information is power. And we believe everyone deserves access to accurate independent coverage of their community and state. Our readers helped us continue this coverage in 2020, and we are so grateful for the support.
Help us keep this coverage going in 2021. Whether it's a one-time acknowledgement of this article or an ongoing membership pledge, your support goes to local-based reporting from our small but mighty team.
Join the Metro Times Press Club for as little as $5 a month.
Subscribe now to get the latest news delivered right to your inbox.